Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | PMM2 | O15305 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672262 | 0.81 | HSD17B10 (0.56) | HSD17B10MAPK1SMN1; SMN2LMNANPC1 | |
| SCHEMBL1945604 | 0.75 | TXNRD1 (0.42) | HSD17B10MAPK1SMN1; SMN2LMNANPC1 | |
| SCHEMBL450293 | 0.72 | ALDH1A1 (0.52) | HSD17B10MAPK1SMN1; SMN2LMNAHTT | |
| SCHEMBL3277269 | 0.72 | PTPRC (0.54) | HSD17B10MAPK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL30317899 | 0.72 | PTPRC (0.54) | HSD17B10MAPK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL527809 | 0.71 | HSD17B10 (0.67) | HSD17B10LMNAALDH1A1PTPRCS100A4 | |
| SCHEMBL30962630 | 0.71 | HSD17B10 (0.67) | HSD17B10LMNAALDH1A1PTPRCS100A4 | |
| SCHEMBL526702 | 0.71 | GPR35 (0.62) | HSD17B10MAPK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7741732 | 0.70 | PTPRC (0.63) | HSD17B10MAPK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11878505 | 0.70 | PLAU (0.54) | ALDH1A1CYP3A4TDP1PLAUGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288376-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-8288376-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8143248-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| EP-1987010-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2010-04-07 | — | — | EP | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| WO-2007088277-A1 | TRICYCLIC Ν-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, CYP3A43 | HSD17B10 1905/4885MAPK1 4560/4885SMN1; SMN2 3560/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | HSD17B10 1941/4885MAPK1 4651/4885SMN1; SMN2 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.